Pharmacological Study for Brain Cancer

Phase 1

Waitlist Available

Led By Manmeet Ahluwalia, MD

Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 - day28 (first cycle)

Awards & highlights

No Placebo-Only Group

Summary

This trial studies the best dose and side effects of terameprocol in patients with recurring high-grade glioma. Terameprocol is a chemotherapy drug that aims to stop cancer cells from growing, dividing, or spreading.

Eligible Conditions

Brain Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 - day28 (first cycle)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 - day28 (first cycle)

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 - day28 (first cycle) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in terameprocol tumor to plasma concentration ratio (Part 2)

Maximum tolerated days of terameprocol dosing that can safely be administered on a continuous basis (Part 3)

Maximum tolerated dose of terameprocol (Part 1)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (terameprocol)Experimental Treatment2 Interventions

Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Pharmacological Study

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Terameprocol

2018

Completed Phase 1

~20

Do I qualify?Apply below to find out